Pennsylvania continues to see rapid shifts in the unregulated drug supply. A new veterinary sedative — medetomidine — is being detected in combination with fentanyl and other substances. As a potent alpha-2 agonist, medetomidine can produce a distinctive withdrawal syndrome, including severe agitation, hypertension, tachycardia, vomiting and seizure-like tremors. Medetomidine withdrawal syndrome can be so severe it may require hospital admission for treatment.
This webinar for Pennsylvania clinicians will review what we currently know about medetomidine and its effects along with an overview of clinical presentation and withdrawal management considerations.